Aesthetic Connect Public Company LimitedSET: TRP🇹🇭 TH

Board Performance · 2025

Compliance Monitoring — Overview

Monitoring of Compliance with Other CG Policies & Guidelines

The company places great importance on corporate governance and has established policies and practices related to corporate governance and business ethics. It also promotes genuine implementation to build trust among all stakeholders. In the past year, the company has monitored the compliance with good corporate governance practices, covering the following areas:

1. Employee care and non-discrimination

2. Anti-competitive practices

3. Environmental care, health, and safety in the organization.

4. Information security

The monitoring results show that the company has fully implemented the guidelines for each of these areas.

Prevention of Conflicts of Interest

Introduction

The Company has established a policy regarding the prevention of conflicts of interest based on the principle that any decision in conducting business activities must be made in the best interest of the Company and its shareholders only and should avoid actions that cause There is a conflict of interest by requiring the executive director And employees who are involved or have an interest in the items being considered must notify the company of their relationship or interest in the said item. and must not participate in the consideration and approval authority of such transactions. At the Board of Directors' meeting No. 1/2023 on February 23, 2023, a resolution was passed to approve the policy regarding the prevention of conflicts of interest.

Has the Company Acted to Prevent Conflicts of Interest?

Yes

Operations in the Past Year

In 2025, the company reviewed its Conflict of Interest Prevention Policy during the Board of Directors' Meeting No. 1/2025 on February 21, 2025. The policy was subsequently communicated to all directors, executives, and relevant stakeholders to ensure compliance with the following guidelines:

(1) Directors, executives, and employees should refrain from engaging in businesses of the same nature and in competition with the company’s business, whether such actions are taken for their own benefit or for the benefit of others, which may cause damage to the company, directly or indirectly. This includes becoming a partner, a shareholder with decision-making power, a director, or an executive in a business of the same nature and in significant competition with the company. Exceptions apply if the company has mechanisms in place to ensure that such actions will not negatively impact the company and will serve the best interests of the company and its shareholders. In any case, if a director, executive, or employee engages in a business of the same nature and in competition with the company, they must report it to the company immediately.

(2) Directors and executives should disclose any business transactions or activities in which they, their family members, relatives, or dependents are personally involved, which may lead to a conflict of interest with the company. This includes investments or interests in business partners or customers of the company, as well as holding any positions, including advisory roles, in business partners or customers of the company, regardless of whether such sales or services are conducted directly or indirectly with the company.

(3) Directors, executives, and employees of the company must make business operation decisions with the primary focus on the best interests of the company.

(4) Directors, executives, and employees of the company must avoid engaging in related-party transactions that may create conflicts of interest with the company. If such transactions are necessary, they must be conducted in the best interests of the company. Decisions and actions taken by directors, executives, and employees must be free from personal influence or influence from any related persons, whether by blood relation or otherwise. Such transactions must be carried out at fair and reasonable prices, comparable to dealings with external parties. If directors, executives, or employees need to approve or decide on transactions that may create conflicts of interest, they must report to their supervisor for approval. The individuals involved must not participate in the decision-making process.

(5) Directors, executives, and employees of the company must perform their duties with full dedication and effort, without engaging in any personal businesses that affect their responsibilities or working hours at the company.

(6) Directors, executives, and employees of the company must not engage in or participate in any business activities that compete with the company. They must not become partners, shareholders with decision-making power, directors, or executives in a competing business, whether they benefit directly or indirectly from such involvement.

(7) Directors, executives, and employees of the company must avoid financial involvement and/or relationships with external parties that may result in the company losing benefits or create conflicts of interest, thereby hindering the company’s operational efficiency.

(8) Directors, executives, and employees of the company must not disclose or use the company’s internal information for their own or others’ benefit, regardless of whether such actions cause harm to the company. Additionally, they must strictly comply with the company’s internal information usage policy.

(9) Directors, executives, and employees of the company must not engage in management or administrative actions that undermine the company’s interests or favor other individuals or legal entities, whether such actions are taken for their own benefit or for the benefit of others.

(10) Directors and executives must abstain from voting or participating in discussions and must not have any authority to approve transactions in which they have conflicts of interest. This also applies to transactions involving related parties or persons with vested interests that may result in conflicts of interest with the company. If directors or executives are involved in such transactions, they must disclose their relationships or interests in the transaction to the company.

Number of Conflict-of-Interest Cases

MetricCurrent YearPrevious YearTwo Years Ago
Total number of cases or issues related to conflicts of interest (cases)000

Prevention of the Use of Inside Information

Introduction

The Board of Directors' Meeting No. 1/2023 on February 23, 2023 resolved to approve the policy on the use of internal information in the company to supervise directors and executives in using internal information of the company which has not yet been disclosed to the public for personal gain. Provide knowledge to executive directors, including those holding management positions in accounting or finance who are department manager level or above or equivalent. Concerning the duty to prepare and submit a report on securities holdings to the Securities and Exchange Commission, including reporting the acquisition or sale of securities, as well as preparing and submitting a report on securities holdings, including suspending the trading of the company's securities. During the period before publishing financial statements or publishing information about the financial status and status of the company until the company has disclosed information to the public, when resigning, it is prohibited to reveal internal information or secrets of the company at all times. Until the secret information of the company's trading partners that they have learned from performing their duties has been disclosed to outsiders, even though the disclosure of such information will not cause any damage to the company and its trading partners, and the company will set strict limits. Disciplinary punishment if there is a violation of using inside information for personal gain.

Has the Company Acted to Prevent the Use of Inside Information?

Yes

Operations in the Past Year

In 2025, the policy on reporting securities holdings and the use of inside information was reviewed during the 1st/2025 Board of Directors meeting on February 21, 2025. The revised policy was communicated to all directors, executives, and relevant parties, who signed to acknowledge their responsibilities. These responsibilities include reporting their securities holdings in the company, as well as those of their spouses and minor children, and ensuring proper handling of inside information. The policy also outlines measures to govern directors and executives in handling non-public company information, as follows:

1. Education and Compliance

The company provides training for directors, executives, and senior managers in accounting or finance (department manager level or equivalent) on their duty to prepare and submit securities holding reports for themselves, their spouses, and their minor children. These reports must be submitted to the Securities and Exchange Commission (SEC) in compliance with Section 59 and the penalties under Section 275 of the Securities and Exchange Act B.E. 2535 (1992) (including subsequent amendments). Additionally, reports on securities acquisitions or disposals by these individuals must also be submitted under Section 246, with penalties as stated in Section 298 of the Act.

2. Reporting Requirements

Directors, executives, and senior managers in accounting or finance must submit their securities holding reports, including those of their spouses and minor children, to the company secretary before forwarding them to the SEC. These reports must be submitted: Within 30 days of being appointed as a director or executive. Within 3 business days of any securities transactions, including purchases, sales, transfers, or acquisitions.

3. Restrictions on Trading Before Public Disclosures

Directors, executives, senior managers in accounting or finance, and employees with access to material non-public information must refrain from trading company securities before financial reports or significant financial updates are disclosed to the public. The company will issue a formal written notice instructing these individuals to refrain from trading company securities for at least one month before public disclosure. After disclosure, they should wait at least 24 hours before engaging in securities transactions. Sharing material non-public information with others is strictly prohibited.

4. Confidentiality Obligation

Directors, executives, employees, and former employees are prohibited from disclosing the company’s confidential or insider information, including business partner information acquired during their tenure, to external parties. This applies even if such disclosure does not directly harm the company or its partners.

5. Disciplinary and Legal Consequences

Violations of the company’s policies on insider information misuse will result in disciplinary action, including written warnings, salary deductions, suspension without pay, or termination. Penalties will be determined based on intent and the severity of the violation. Individuals who misuse insider information for personal gain, including any related parties, may also face legal consequences under applicable laws.

In addition, the Company Secretary has prepared and notified directors and executives in advance of the blackout periods for trading the Company’s securities, together with the Board of Directors’ meeting schedule, as follows:

  • Board of Directors’ Meeting Date: 21 February 2025
    Blackout Period: 21 January 2025 – 24 February 2025

  • Board of Directors’ Meeting Date: 9 May 2025
    Blackout Period: 9 April 2025 – 13 May 2025

  • Board of Directors’ Meeting Date: 8 August 2025
    Blackout Period: 8 July 2025 – 11 August 2025

  • Board of Directors’ Meeting Date: 7 November 2025
    Blackout Period: 7 October 2025 – 10 November 2025

Number of Inside-Information Cases

MetricCurrent YearPrevious YearTwo Years Ago
Total number of cases or issues related to the use of inside information to seek benefits (cases)000

Anti-Corruption

Introduction

The Board of Directors’ Meeting No. 1/2023, held on 23 February 2023, approved the Anti-Corruption Policy and stipulated that such policy be reviewed at least once annually. In 2025, the policy was reviewed at the Board of Directors’ Meeting No. 1/2025, held on 21 February 2025.

The Company recognizes the importance of management and business operations under the principles of good corporate governance, adhering to integrity, honesty, and transparency. Accordingly, the Company has established an Anti-Corruption Policy to ensure that directors, executives, and employees of the Group avoid any actions that may involve corruption in any form, whether for direct or indirect benefit to themselves, their families, or related persons.

In addition, the Company has established a clear organizational structure with well-defined roles and responsibilities, work processes, and reporting lines within each department to ensure appropriate checks and balances, as well as effective internal control mechanisms.

Has the Company Acted on Anti-Corruption?

Yes

Operations in the Past Year

Anti-Corruption Operation Approach

Review of Appropriateness

The Company has reviewed the appropriateness of its anti-corruption practices. On 20 February 2025, the Audit Committee Meeting No. 1/2025 reviewed the Anti-Corruption Policy and subsequently proposed it to the Board of Directors for consideration and approval.


Risk Assessment of Corruption

The risk management team has assessed and managed risks related to corruption that may arise from business operations and the company’s reputation. Measures and guidelines to prevent risks have been developed and presented to the Audit Committee. Additionally, the internal auditor has conducted an audit of the company’s internal control system for corruption in accordance with the audit plan. The internal auditor, being an independent external auditor, reports the audit results directly to the Audit Committee.


Guidelines for Conduct

The company has established strict guidelines for the board members, executives, and employees to follow, prohibiting any involvement in corruption in all forms, both direct and indirect, as follows:

1. Do not engage in any behavior that demonstrates an intention of corruption, including giving or receiving bribes from government officials, private sector employees, or stakeholders involved with the company, to secure or maintain business, competitive advantages, or personal benefits for themselves or others.

2. Do not ignore or neglect any actions that may involve corruption related to the company. It is the responsibility to report such actions to the supervisor or the responsible individual and cooperate in investigating the facts.

3. The company will ensure fairness and protection for individuals who refuse to participate in corruption or report corruption issues to the company, as specified in the whistleblower protection measures or for those who cooperate in reporting corruption.

4. Any individual engaging in corruption will violate the company's ethical standards and business conduct, and will face disciplinary actions according to the company's regulations. If the actions are illegal, legal penalties may also apply.

5. The company recognizes the importance of disseminating knowledge and ensuring understanding among those who perform duties related to the company or who may impact the company, to comply with the anti-corruption policy.

6. The company ensures that there is an appropriate and effective internal control system that is regularly reviewed to prevent corruption and improve work efficiency while minimizing risks. The internal control system includes both preventive and detective controls to reduce opportunities and incentives for misconduct and corruption. These include work role segregation, continuous monitoring, and prompt reporting by management regarding any irregularities or deficiencies, as well as improving preventive measures.

7. The company has an HR management process reflecting the company’s commitment to anti-corruption measures, from selection, training, performance evaluation, compensation, and promotion.

8. To ensure clarity in high-risk corruption areas, board members, executives, and employees at all levels must act with caution in the following matters:

8.1. Giving or receiving gifts and hosting events must be transparent, legal, in accordance with normal business practices, or customary traditions with appropriate value.

8.2. Donations or financial contributions must be transparent and legal, ensuring that such donations are not a cover for bribery.

8.3. Business operations, communications, negotiations, bidding, and other activities with government or private entities must be transparent and legal. Additionally, executives and employees must not give or accept bribes at any stage of operations.


The communication of these policies and guidelines has been shared with employees through the company’s communication channels and via the company website at https://trphospital.com/en/corporate-governance/ to ensure that all executives and employees are informed and comply.

Form of Anti-Corruption Operations

Operation
Review of appropriateness in anti-corruption
Assessment and identification of corruption risk
Communication and training for employees on anti-corruption policy and guidelines
The monitoring of the evaluation of compliance with the anti- corruption policy
Review of the completeness and adequacy of the process by the Audit Committee or auditor

Number of Corruption Cases

MetricCurrent YearPrevious YearTwo Years Ago
Total number of cases or issues related to corruption (cases)000

Whistleblowing

Introduction

The company has implemented measures for whistleblowing and complaint reporting regarding legal violations, business ethics, and any behavior that may indicate fraud or corruption by directors, executives, or employees within the corporate group. Various communication channels have been established to provide employees and stakeholders with convenient and appropriate means to report misconduct or complaints to the company. Whistleblowers or complainants must provide details of their report, including their name, address, and contact number, and submit them through the designated reporting channels.

1. Whistleblowing and Corruption Complaint Reporting Channels Reports can be submitted to the Audit Committee via telephone or the Audit Committee Secretary’s email at whistleblower@teerapornhospital.com, or Through the website of Aesthetic Connect Public Company Limited at https://trphospital.com/
Note: Once the Audit Committee Secretary registers complaints received via electronic or physical mail, the relevant department will be notified for further action as follows:

  • If the complaint involves violations or non-compliance with personnel policies and procedures, it will be forwarded to the Human Resources Department.

  • If the complaint involves violations or non-compliance with laws, government regulations, corporate governance policies, business ethics, or the company’s rules and regulations, it will be forwarded to the Audit Committee Secretary.

  • If the complaint involves suspected fraudulent activities, including any actions aimed at obtaining unlawful benefits for oneself or others—such as embezzlement, corruption, or fraud—it will be forwarded to the Audit Committee.

  • If the complaint under items 1–3 is complex or involves multiple departments, it will be escalated to the Chief Executive Officer (CEO).


2. Protection Measures and Confidentiality

To protect the rights of complainants and whistleblowers who act in good faith, the company will keep their names, addresses, and any identifiable information confidential. The information will be securely maintained and accessible only to those responsible for investigating the complaint. In cases involving allegations of corruption by executives, the Audit Committee will ensure the protection of whistleblowers, complainants, witnesses, and individuals providing information during the investigation process. They will be safeguarded from distress, harm, or unfair treatment resulting from their reporting, testifying, or providing information. Personnel responsible for handling complaints must strictly maintain the confidentiality of all complaints and related evidence. They are prohibited from disclosing any information to unauthorized individuals, except as required by law.

Has the Company Implemented Whistleblowing Procedures?

Yes

Operations in the Past Year

The Company has established whistleblowing channels via the Company’s website to provide stakeholders with convenient and confidential means to report information or submit complaints. In 2025, no whistleblowing reports were received by the Company.

Number of Whistleblowing Cases

MetricCurrent YearPrevious YearTwo Years Ago
Total number of cases or issues received through whistleblowing channels (cases)000

Selection of Directors & Chief Executives

Selection — Introduction

The Nomination and Remuneration Committee was appointed at the Board of Directors Meeting No. 1/2566 of Aesthetic Connect Public Company Limited, held on February 23, 2023. The committee is responsible for recruiting, selecting, and proposing suitable candidates for the position of company director. According to the Board Charter, the Board of Directors must consist of at least five members, with no less than half (1/2) of the total board members residing in Thailand. Additionally, the board must include at least three independent directors or at least one-third of the total number of board members. Independent directors must meet all nine qualifications specified for independent directors. Furthermore, company directors must meet the following qualifications:

1. Must fully meet the qualifications of a director as stipulated by the Public Limited Companies Act, the Securities and Exchange Act, and the company’s regulations. Additionally, they must not possess any prohibited characteristics as defined by the Public Limited Companies Act and must not exhibit any traits that indicate a lack of suitability to be entrusted with managing a publicly held company, as specified by the Securities and Exchange Commission (SEC) regulations.

2. Must demonstrate leadership, a broad vision, and a strong understanding of the company’s business operations.

3. All board members must be able to perform their duties and express their opinions independently while dedicating sufficient time to fulfill their responsibilities.


Director Nomination

The Nomination and Remuneration Committee is responsible for establishing the criteria and policies for the nomination and remuneration of the Board of Directors and sub-committees. It is also tasked with identifying, selecting, and proposing suitable candidates for directorship positions and determining the remuneration for the Board of Directors. The details are as follows:

1. Establish criteria and policies for the nomination of the Board of Directors and sub-committees by considering the appropriateness of the number, structure, and composition of the board. Define the qualifications of directors to propose to the Board of Directors and/or seek approval from the shareholders' meeting as applicable.

2. Consider, nominate, select, and propose suitable candidates for the position of directors whose terms have ended and/or to fill vacant positions and/or for additional appointments.

3. Carry out other recruitment-related tasks as assigned by the Board of Directors.

4. Evaluate the performance of the company's top executive and present the assessment to the Board of Directors for consideration and approval.

Additionally, the company has granted shareholders the right to nominate individuals they deem qualified for election as company directors, with the nomination announcement posted on the company's website. However, no shareholders have proposed any candidates for election as company directors.

Directors & Chief Executives — Introduction

The Nomination and Remuneration Committee is responsible for considering and selecting directors, sub-committee members, and the Chief Executive Officer (CEO), ensuring they meet all the required qualifications as per the company's guidelines for board members, independent directors, and the CEO. In addition to meeting these qualifications, candidates must possess the necessary knowledge, skills, and work experience that align with the company’s business strategy. They must also be committed to dedicating sufficient time to effectively perform their duties as directors

1.1 Composition of the Board of Directors The Board of Directors shall consist of at least 5 members, with no less than half (1/2) of the total number of directors having their domicile in Thailand. The board must include at least 3 independent directors, or at least one-third of the total number of directors.

1.2 Shareholders shall be responsible for approving the appointment of the Board of Directors.

1.3 The Board of Directors shall select one member to serve as the Chairman of the Board.

1.4 The appointment of the Board of Directors shall comply with the company’s regulations and applicable legal requirements, ensuring transparency and clarity in the decision-making process, which must be based on the shareholders’ consideration.

Qualifications of Board Members

1. The board member must meet all qualifications as specified in the Public Limited Companies Act, the Securities and Exchange Act, and the company's regulations. Additionally, the individual must not have any disqualifications as defined by the law governing public limited companies, nor exhibit any characteristics that would make them unsuitable to be entrusted with managing a business that has public shareholders, as declared by the Securities and Exchange Commission.

2. The board member must possess leadership qualities, a broad vision, and an understanding of the company’s business operations.

3. All board members must be able to perform their duties and express their opinions independently. They must also be able to dedicate sufficient time to fulfill their responsibilities.

Selection of Executive Directors, Chief Executive Officer (CEO), and Senior Executives

At the first meeting of the Board of Directors in 2023, held on February 23, 2023, the Board approved the succession policy, which outlines the steps and processes for the succession of the Chief Executive Officer (CEO) and other senior executive positions. This is to ensure that the company has competent and capable executives to fill these key positions in the future.

1. Chief Executive Officer (CEO) Level

The selection and succession planning for the CEO position is managed by the Nomination and Remuneration Committee. This committee is responsible for creating a succession plan for the CEO, which is then submitted for review and approval by the Board of Directors. In the event that the CEO position becomes vacant, or the current CEO is unable to fulfill their duties, the Nomination and Remuneration Committee will follow the succession plan. The company will appoint an executive from a similar or senior level to act as the interim CEO until a qualified individual is selected and appointed, in accordance with the company's criteria. The candidate for the CEO position must possess vision, knowledge, competence, experience, and alignment with the company's culture. The Nomination and Remuneration Committee will evaluate potential candidates to ensure they meet these qualifications, have the necessary skills and experience for the company’s operations, and fully understand the business. The selected individual must be able to lead the company towards achieving its goals and objectives as outlined by the Board of Directors. After evaluation, the committee will propose the appointment of the selected candidate to the Board for final approval. This process aims to maintain investor and organizational confidence and ensure the continuity of the company's operations without disruption.

2. Deputy Chief Executive Officer / Hospital Director Level

The Company considers recruitment/selection and succession planning for the Deputy Chief Executive Officer/Hospital Director level, with the Nomination and Remuneration Committee responsible for preparing the succession plan for such positions for submission to the Board of Directors for consideration. In recruiting and selecting candidates for the Deputy Chief Executive Officer/Hospital Director positions, the Nomination and Remuneration Committee monitors the progress of the succession plan. In the event that such positions become vacant or the incumbent is unable to perform their duties, the Company has a system in place to appoint an acting executive at an equivalent level or at the Deputy Chief Executive Officer/Hospital Director level until a suitable candidate, meeting the Company’s specified qualifications, is recruited and selected. The candidate must possess vision, knowledge, capabilities, experience, and be aligned with the Company’s organizational culture.

For the recruitment of executives at the Deputy Chief Executive Officer/Hospital Director level, the Nomination and Remuneration Committee will conduct an initial screening to identify candidates with appropriate qualifications, knowledge, competencies, skills, and experience beneficial to the Company’s operations, as well as a strong understanding of the Company’s business. Such candidates must be capable of managing the organization to achieve the objectives and goals set by the Board of Directors. The shortlisted candidates will then be proposed to the Board of Directors for approval and appointment. This process aims to maintain confidence among investors, the organization, and employees that the Company’s operations will continue seamlessly and in a timely manner.

3. Executive level, starting from the Director level

When an executive position, starting from the Director level, becomes vacant or the incumbent is unable to perform their duties, the company will present the selected successor to the Executive Committee and/or the appointed committee responsible for recruitment/selection. The company’s succession planning process for executive positions is as follows:

3.1 Analyze the company’s business situation in terms of strategy, policies, investment plans, and expansion plans.

3.2 Evaluate the readiness of human resources to align with the company’s strategies, both short-term and long-term.

3.3 Develop a human resource readiness plan by either developing employees or recruiting new employees to replace those who leave.

3.4 Create recruitment and training plans in advance for employees who will retire or leave their positions prematurely.

3.5 Define the qualifications and competencies required for the position, which include knowledge, skills, personality traits, and attitudes. Additionally, create an Individual Development Plan (IDP) for each employee.

3.6 Select, assess performance, and evaluate the potential of employees to determine suitability for the position.

3.7 Utilize assessment tools to analyze the potential of employees.

3.8 Identify successors based on performance evaluation and potential analysis. Inform the employees in advance to prepare for the handover and learning process, and establish backup successors.

3.9 Develop and evaluate potential successors to determine if they can meet the expected development and performance targets. If the expectations are not met, the following actions will be taken:

3.9.1 Select and plan a new succession, or

3.9.2 Develop the backup successor (if available), or

3.9.3 Recruit and select from external candidates if the successor meets the qualifications required for a higher position with increased responsibilities. If there is a vacant position or a newly created higher position, propose promotions and acting appointments according to the company’s position structure policy. The promotion criteria will be reviewed and approved by the CEO and the Executive Chairman.

Selection Process — Introduction

The Nomination and Remuneration Committee is responsible for selecting and nominating qualified individuals for consideration by the Board of Directors and the shareholders' meeting for appointment, in accordance with the company's regulations.

Are Directors Selected Through the Nomination Committee?

Yes

Are Chief Executives Selected Through the Nomination Committee?

Yes

Number of Directors from Major Shareholders

0

Rights of Minority Shareholders on Director Appointment

The company grants shareholders the right to nominate individuals they deem qualified for consideration in the election of the company's directors. This opportunity is announced on the company's website, and the Corporate Secretary is responsible for compiling the nominations and submitting them to the Nomination and Remuneration Committee for review. The committee evaluates the qualifications of the nominated individuals before providing recommendations to the Board of Directors, which then decides whether to present the nominees to the shareholders' meeting for further consideration. However, no shareholders have submitted any nominations for director election.

Method of Director Appointment

Method
Method whereby each director requires approval votes more than half of the votes of attending shareholders with voting rights

Selection of Independent Directors

Criteria for Selecting Independent Directors

The Nomination and Remuneration Committee will jointly consider the qualifications of individuals to be appointed as independent directors, based on the qualifications and disqualifications of directors under the Public Limited Companies Act, the Securities and Exchange Act, the announcements by the Securities and Exchange Commission, the Capital Market Supervisory Board, the Stock Exchange of Thailand, as well as relevant regulations and/or rules. These will be presented to the Board of Directors for consideration. The Board will select independent directors from qualified individuals with relevant work experience and other appropriateness factors, in alignment with the company’s strategy and business operations. The selected candidates will then be presented to the shareholders’ meeting for approval of their appointment as directors of the company. According to the Board of Directors' Charter, the Board must consist of at least 5 directors, with no less than half (1/2) of the total number of directors having a domicile in Thailand. The Board must include no less than 3 independent directors, or at least one-third (1/3) of the total Board members. The independent directors must meet the following qualifications:

1.Does not hold more than 1% of the total voting shares of the company, the parent company, subsidiaries, affiliates, major shareholders, or controlling persons of the company. This includes shares held by related persons of the independent director.

2. Has never been or is not currently an executive director, employee, salaried consultant, or controlling person of the company, the parent company, subsidiaries, affiliates, major shareholders, or controlling persons of the company, unless at least 2 years have passed since holding such position.

3.Is not a person who is a relative by blood or law of any other director, executive, major shareholder, controlling person, or any individual proposed to be appointed as a director, executive, or controlling person of the company or its subsidiaries.

4.Has no business relationship or has never had a business relationship with the company, the parent company, subsidiaries, affiliates, major shareholders, or controlling persons of the company in a way that could interfere with the independent judgment. This includes not being or having been a significant shareholder or controlling person of a business with such relationships, unless at least 2 years have passed since the end of such a relationship.

5.Has never been an auditor of the company, the parent company, subsidiaries, affiliates, major shareholders, or controlling persons of the company, and is not a significant shareholder, controlling person, or partner in the audit firm where auditors of the company, the parent company, subsidiaries, affiliates, major shareholders, or controlling persons of the company are employed, unless at least 2 years have passed since the end of such a relationship.

6.Has never provided professional services, including legal or financial consulting services, for a fee exceeding 2 million Baht per year from the company, the parent company, subsidiaries, affiliates, major shareholders, or controlling persons of the company, and is not a significant shareholder, controlling person, or partner of the service provider, unless at least 2 years have passed since the end of such a relationship.

7.Has never been appointed as a director to represent the directors of the company, major shareholders, or shareholders related to major shareholders.

8.Does not operate a business that competes directly with the company or its subsidiaries, nor is a partner with a significant interest in a partnership or a director with management duties, employee, salaried consultant, or holds more than 1% of the voting shares in any other company that competes directly with the business of the company or its subsidiaries.

9.Has no other characteristics that would prevent them from giving an independent opinion regarding the operations of the company.

Business or Professional Relationships — Introduction

As of December 31, 2025, the company had three independent directors: Clinical Professor Dr. Apichati Sivayathorn, Mr. Somboon Wongrassamee, and Mr. Kirkchai Chaiyatham. Throughout the past year, all three independent directors had no business relationships with the company and did not provide any professional services to the company.

Did Any Independent Director Have a Business or Professional Relationship?

No

Director Development

Director Development — Introduction

The company has a policy to promote the development of knowledge, skills, and competencies for directors, executives, and employees, ensuring they are well-equipped for both current and future responsibilities. The company recognizes that its personnel are a vital asset and aims to support their growth and career advancement alongside the company. This is achieved through training programs and seminars, both internally and externally, in collaboration with specialized institutions, as deemed appropriate. All company directors have completed 100% of the training courses specifically designed for directors. The details of these courses are provided in Appendix 1.

Development of Directors in the Past Year

During the period from 2021 to 2025, the Board of Directors attended various training programs beneficial to the management of the organization, as follows:

Qualifications for Director Selection — Introduction

Qualifications of Directors for Nomination

  1. Must not possess any prohibited characteristics under the Public Limited Companies Act, the Securities and Exchange Act, or any other relevant laws, including notifications of the Office of the Securities and Exchange Commission, the Capital Market Supervisory Board, the Stock Exchange of Thailand, or any other applicable regulations, as well as the Company’s Articles of Association.

  2. Must have experience beneficial to the Company’s business operations, as well as appropriate knowledge, capabilities, and experience in managing the Company in accordance with the Board Skill Matrix. Directors must demonstrate integrity, honesty, and ethical conduct in management, and the Company shall utilize a directors’ database as part of the nomination process for new directors.

  3. Independent directors must possess qualifications in accordance with the criteria prescribed by the Office of the Securities and Exchange Commission and the Stock Exchange of Thailand.

Evaluation of Board & Subcommittee Performance

Evaluation — Introduction

The Nomination and Remuneration Committee conducts an annual performance evaluation of the Board of Directors, subcommittees, and the Chief Executive Officer, at least once a year. The evaluation includes both a collective assessment of each committee and a self-assessment on an individual basis. The committee adopts and adapts self-assessment guidelines from the Stock Exchange of Thailand as a framework for monitoring performance, reviewing achievements, identifying challenges and obstacles encountered throughout the year, and incorporating feedback for improvement. This process aims to enhance the effectiveness of the Board of Directors and the Chief Executive Officer, ensuring that governance, oversight, and management practices align with good corporate governance principles.


Evaluation Criteria for the Performance of the Board of Directors and Subcommittees Board

1. Structure and Qualifications – Ensuring that the board's composition and qualifications are appropriate to enhance the efficiency of its operations.

2. Board Meetings – Evaluating the effectiveness of board meetings in enabling directors to perform their duties efficiently.

3. Roles, Duties, and Responsibilities – Assessing whether the board adequately prioritizes, reviews, and fulfills its responsibilities with sufficient time and attention.

4. Other Matters – Additional relevant considerations for the board’s performance evaluation.


Evaluation Criteria for the Performance of Individual Directors and Sub-Committee Members

1. Board Structure and Qualifications

2. Board Meetings

3.Roles, Duties, and Responsibilities of the Board

Evaluation Criteria — Introduction

Evaluation Process:

1.The Nomination and Compensation Committee establishes the evaluation form and criteria for scoring the evaluation.

2.The company secretary submits the evaluation forms, both by committee and individual, to all board members.

3.The board members complete the evaluation form. The company secretary collects and summarizes the evaluation results and reports them to the Nomination and Compensation Committee for submission to the board of directors for acknowledgment at the first meeting of the year. Any recommendations will be used to improve work efficiency for the maximum benefit of the business operations and corporate governance going forward.

Criteria for Evaluating Board Performance

In 2025, the evaluation results were reported to the Board of Directors at Meeting No. 1/2026, held on 27 February 2026.

Evaluation Criteria and Scoring Summary for Each Item (Out of a Total Score of 4.00):

- Score 3.90 - 4.00: Evaluation Criteria – Excellent

- Score 3.80 - 3.89: Evaluation Criteria – Very Good

- Score 3.50 - 3.79: Evaluation Criteria – Good

- Score 3.00 - 3.49: Evaluation Criteria – Fair

-Score Below 3.00: Evaluation Criteria – Needs Improvement

Evaluation of Board Performance in the Past Year

Board Performance Evaluation Summary for 2025

Board (by committee): Average score of 3.82, rated "Very Good."

Board (by individual): Average score of 3.85, rated "Very Good."


Sub-Committee Performance Evaluation Summary for 2025

Audit Committee (by committee): Average score of 3.91, rated "Excellent."

Audit Committee (by individual): Average score of 3.92, rated "Excellent."

Nomination and Compensation Committee (by committee): Average score of 3.98, rated "Excellent."

Nomination and Compensation Committee (by individual): Average score of 3.94, rated "Excellent."

Executive Committee (by committee): Average score of 4.00, rated "Excellent."

Executive Committee (by individual): Average score of 4.00, rated "Excellent."

Corporate Governance Committee (by committee): Average score of 3.96, rated "Excellent."

Corporate Governance Committee (by individual): Average score of 3.94, rated "Excellent."


The CEO performance evaluation for 2025, held by Prof. Dr. Choladhis Sinrachtanant, had an average score of 3.89, rated "Very Good."

Evaluation Results

Evaluated BodyGroup — Carried Out?Group — Grade / Average ScoreGroup — Grade / Full ScoreIndividual (Self-Assessment) — Carried Out?Individual (Self-Assessment) — Grade / Average ScoreIndividual (Self-Assessment) — Grade / Full ScoreCross (Assessing Other Directors) — Carried Out?
Board Of DirectorY3.824.00Y3.854.00N
Audit CommitteeY3.914.00Y3.924.00N
Other SubcommitteeY3.984.00Y3.944.00N
Executive CommitteeY4.004.00Y4.004.00N
Other SubcommitteeY3.964.00Y3.944.00N

Subcommittees

Subcommittees

Results of the Subcommittee's Duty Performance

In 2025, the Nomination and Remuneration Committee performed its duties in accordance with its Charter. The key activities are summarized as follows:

  1. To review the Nomination and Remuneration Committee Charter to ensure that its roles and responsibilities remain appropriate for the Company’s business operations and aligned with current circumstances

  2. To consider and approve the performance evaluation results of the Board of Directors, sub-committees, and the Chief Executive Officer (for 2024), and propose them to the Board of Directors for approval

  3. To consider the nomination and re-appointment of directors retiring by rotation for another term, based on qualifications in compliance with legal requirements, absence of prohibited characteristics, integrity, knowledge, capability, proven performance, ability to contribute value to the organization, and dedication of time, and to propose such nominations to the Board of Directors and the 2025 Annual General Meeting of Shareholders for approval

  4. To consider and endorse the appointment of a Deputy Chief Executive Officer to fill a vacant position, and propose such appointment to the Board of Directors for approval

  5. To consider and endorse the appointment of a director to replace a resigning director, and propose such appointment to the Board of Directors for approval

  6. To consider the remuneration and directors’ bonuses for the Board of Directors and subcommittees for the year 2025, based on the Company’s established criteria and appropriateness, and to propose such matters to the Board of Directors for approval prior to submission to the Annual General Meeting of Shareholders for consideration and approval.

The Nomination and Remuneration Committee has performed its duties as stipulated in its Charter, as well as other assignments from the Board of Directors, with due care and prudence, taking into consideration the Company’s operating performance and the overall economic conditions, with the objective of creating maximum benefit for shareholders and all stakeholders.

The Corporate Governance Committee has fully performed its duties as assigned in accordance with its Charter. The key activities are summarized as follows:

  1. To support, promote, and monitor the management in conducting business operations with due consideration for environmental impact, social responsibility, and adherence to good corporate governance principles, as an integral part of the Company’s strategy and annual business plan, and to integrate such practices into normal operations to effectively respond to all stakeholder groups

  2. To approve sustainability policies and targets under the ESG (Environmental, Social, and Governance) framework. In 2025, the key targets approved include:

    • Reduction of greenhouse gas emissions by 1% compared to the base year (2021)

    • Electricity expenses not exceeding Baht 4,650,000 per year

    • Water expenses not exceeding Baht 58,500 per year

    • Waste management, with infectious waste limited to an average of no more than 80 kilograms per month or 960 kilograms per year, and related expenses not exceeding Baht 24,000 per year

  3. To consider guidelines for the development and training of directors

  4. To approve participation in the Corporate Governance Report of Thai Listed Companies (CGR) survey and the AGM Checklist assessment project

  5. To report the results of compliance with the 2025 Corporate Governance principles, covering all 8 core principles of Corporate Governance

  6. To review the Corporate Governance Committee Charter and the Company’s Corporate Governance Policy

  7. To conduct performance evaluations of the Corporate Governance Committee, both on a collective and individual basis, for the year 2025. The overall evaluation result was rated “Excellent”, and the results were reported to the Board of Directors to enhance performance efficiency and disclosed in the Form 56-1 One Report

  8. To schedule the Corporate Governance Committee meeting for 2026 in advance, as follows:

    • Meeting No. 1/2026: Friday, 20 February 2026, 5:00 – 6:00 PM

As a result of these efforts, the Company received the following recognitions:

  • A “Very Good” rating in the Corporate Governance Report of Thai Listed Companies (CGR)

  • An AGM Checklist score of 97 points for the 2025 Annual General Meeting, awarded by the Thai Investors Association,

The Corporate Governance Committee remains committed to upholding and supporting responsible business practices in accordance with good corporate governance principles, delivering value to customers and all stakeholders, including the community, society, and the environment, to ensure the Company remains a trusted and sustainable organization.

The performance of the Corporate Social Responsibility (CSR) Committee has been summarized and reported on a quarterly basis to the Board of Directors. The key matters are as follows:

  1. Consideration has been given to reviewing the Charter and policies related to Corporate Social Responsibility (CSR) on an annual basis to ensure alignment with fundamental ethical principles in accordance with the criteria and standards of leading organizations both domestically and internationally. Emphasis is placed on applying good corporate governance principles as a guideline to maintain a balance among economic, community, social, and environmental dimensions, which will lead to sustainable business development.

  2. Consideration has been given to organizing training programs for employees, both within and outside the Company. Each year, the training period, budget, and target participants are clearly defined to enhance employees’ work capabilities, safety, knowledge, and individual competencies. For example, first aid and CPR training programs are provided to refresh and enhance the knowledge of the Company’s personnel so that they are able to perform life-saving procedures in emergency situations.

  3. Consideration has been given to organizing continuous activities for the community and society, with emphasis on minimizing environmental impact and avoiding operations that may negatively affect the quality of life of surrounding communities. The activities carried out include:

    • Teeraporn Hospital organized a food distribution activity for more than 300 construction workers on Friday, 6 January 2025. Dr.Chaiyot Denariyakul , Executive Director of Aesthetic Connect Public Company Limited, led the activity by distributing noodles to the construction workers involved in building the hospital, as a gesture of appreciation for their dedication and contribution to the hospital project. The activity aimed to boost morale among those who play a crucial role in the development of the hospital’s infrastructure. Dr. Chaiyot stated that “every success of the project would not be possible without the sacrifice and commitment of everyone, especially those working behind the scenes in construction, who are the foundation of the hospital.” This activity not only brought smiles and satisfaction to the workers but also reflected the Company’s care and support for all stakeholders in society.

    • The Company supported Somdet Chao Phraya Metropolitan Police Station in organizing National Children’s Day activities, which were warmly attended by more than 100 children in the area. The Company provided prizes and snacks to create happiness and a joyful atmosphere. The event also included performances, games, and creative activities that contributed to the development and well-being of children. The Company believes that supporting youth activities not only brings happiness in the present but also helps build a strong foundation for future societal development. Participation in this event reflects the Company’s commitment to supporting communities and fostering a caring and happy society.

    • Teeraporn Hospital participated in supporting society through the opening of the BKK Food Bank room in Khlong San District on Friday, 24 January 2025. Dr. Kongsak Techawibunphon, Executive Director, attended the event at the Khlong San District Office. The initiative focused on supporting and distributing food and essential items to vulnerable groups. Donations were organized in a manner similar to a convenience store, allowing recipients to select items according to their needs. Dr. Kongsak emphasized that “providing food support not only alleviates short-term hardship but also helps build a sustainable sharing society.” This activity represents an effort to reduce social inequality and improve quality of life through collaboration.

    • Teeraporn Hospital participated in a grand Kathin (robe-offering) ceremony at Wat Thai Buddhagaya, Republic of India. Aesthetic Connect Public Company Limited joined this significant religious event, presided over by Phra Dharmapothiwong (Weerayut Weerayuttho), the abbot of Wat Thai Buddhagaya, together with Dr. Choladhis Sinrachtatant and well-known celebrities, including Tuk Duangta, Dee Chanana, Tai Saitharn, and Champagne X.

    The Company would like to dedicate the merit from this occasion to all Teeraporn customers, wishing them happiness and strong health throughout 2025. Teeraporn remains committed to taking care of all clients, whether for facial rejuvenation procedures, targeted treatments, rhinoplasty, or double eyelid surgery, with assured results delivered by Teeraporn’s highly experienced medical specialists, who have been trusted by celebrities and public figures for over 40 years.

    • Teeraporn Hospital, in collaboration with the Ruamkatanyu Foundation, led by Dr. Choladhis Sinrachtanant, CEO of Aesthetic Connect Public Company Limited, along with public figures, donated essential items and wound care equipment to support disaster-affected individuals. This initiative reflects the Company’s commitment to social recovery and collective well-being.

    • Teeraporn Hospital, in collaboration with the Thonburi District Office, organized a CSR activity on Sunday, 6 July 2025, to provide essential items to 100 underprivileged individuals in the surrounding community and donated rice and dry food to the local Food Bank. The activity received strong support from the district office and reflects the Company’s commitment to ethical business practices and sustainable community engagement.

    • Teeraporn Hospital, together with the Thonburi District Office, donated drinking water to support participants in the “Healthy City @ Krung Thonburi 2nd Edition” running event.

    • Teeraporn Hospital, in collaboration with Somdech Phra Pinklao Hospital, organized a blood donation activity on 17 October 2025. The event was attended by executives, medical staff, customers, and employees who contributed to helping patients in urgent need. The Company recognizes that even a small contribution can create a significant impact on saving lives.

  4. Company Visit – Investor Engagement Activity
    Aesthetic Connect Public Company Limited (“TRP”), led by Dr.Chaiyot Denariyakul, Dr. Kongsak Techawibunphon, and Dr. Thanachak Sinrachtatant, organized the TRP Company Visit to welcome a group of investors on 15 September 2025 at Teeraporn Hospital.

The CSR Committee is committed to promoting value creation for all stakeholders across both economic and social dimensions, while encouraging participation in activities that enhance the quality of life of society, communities, and the environment. The Company ensures that its CSR operations are conducted appropriately, transparently, and effectively, thereby strengthening confidence and trust among all stakeholders in a sustainable manner.

The Committee has fully performed its assigned duties in accordance with the Charter. The key activities are summarized as follows:

  • Thoroughly considered risk factors affecting the Company, including both external and internal risks, and proposed appropriate guidelines and measures to prevent and mitigate such risks to an acceptable level, in order to achieve the Company’s objectives and enhance value creation.

  • Oversaw, monitored, and ensured compliance with the Company’s risk management policy, including periodic review and improvement of such policy to ensure its adequacy, effectiveness, and efficiency in controlling risks.

  • Supervised internal units to conduct comprehensive risk assessments covering business risks, financial risks, operational risks, compliance risks, and emerging risks, in order to establish appropriate risk management plans within acceptable levels. This also includes ensuring that risk management covers anti-corruption risks.

  • Identified, analyzed, and assessed various risk factors, including potential impacts and trends affecting the Company, and developed plans to prevent or mitigate such risks.

  • Regularly reported on operational performance, the Company’s risk status, and any significant changes, including necessary corrective actions to ensure alignment with established policies and strategies, to the Audit Committee for further reporting to the Board of Directors.

In summary, the Risk Management Committee is of the opinion that, in 2025, the Company has established an effective risk management system that is sufficient to oversee the organization’s key risks. The system is appropriate for the nature of the Company’s business and operations and serves as a key driver for sustainable growth and business expansion, while maintaining strong financial stability and delivering appropriate returns to shareholders.

Meeting Attendance & Remuneration

Meeting Attendance — Sub-section Introduction

The Board of Directors’ Meeting No. 4/2025, held on 7 November 2025, resolved to approve the advance scheduling of the dates and times for the Board of Directors’ meetings, Audit Committee meetings, and the Annual General Meeting of Shareholders for 2026, as well as the determination of the blackout periods for securities trading, as follows:

Meeting No. 1/2026

  • Audit Committee Meeting: 26 February 2026, 4:00 – 5:30 PM

  • Board of Directors’ Meeting: 27 February 2026, 5:30 – 7:00 PM

  • Blackout Period: 27 January 2026 – 2 March 2026

Meeting No. 2/2026

  • Audit Committee Meeting: 13 May 2026, 4:00 – 5:30 PM

  • Board of Directors’ Meeting: 14 May 2026, 5:30 – 7:00 PM

  • Blackout Period: 14 April 2026 – 15 May 2026

Meeting No. 3/2026

  • Audit Committee Meeting: 11 August 2026, 4:00 – 5:30 PM

  • Board of Directors’ Meeting: 13 August 2026, 5:30 – 7:00 PM

  • Blackout Period: 13 July 2026 – 14 August 2026

Meeting No. 4/2026

  • Audit Committee Meeting: 11 November 2026, 4:00 – 5:30 PM

  • Board of Directors’ Meeting: 12 November 2026, 5:30 – 7:00 PM

  • Blackout Period: 12 October 2026 – 13 November 2026

Annual General Meeting of Shareholders 2026

  • 29 April 2026 at 2:00 PM

Justification for Directors' Non-Attendance

Remarks:

  1. Mr. Chakchalat Sinrachatanant resigned from his position as a director on 5 August 2025.

  2. Mr. Thanachak Sinrachatanant was appointed as a director on 14 August 2025.

Types of Remuneration of the Board of Directors

The Nomination and Remuneration Committee is responsible for determining policies regarding both monetary and non-monetary remuneration. The process for considering remuneration and other benefits for the Board of Directors and sub-committees must be transparent and at a level comparable to companies within the same industry. Key factors taken into consideration include duties, scope of work, roles, and responsibilities. The remuneration of directors must be approved by the shareholders’ meeting.

The Annual General Meeting of Shareholders for the year 2025, held on 28 April 2025, resolved to approve the remuneration of the Board of Directors and sub-committees for 2025. The remuneration structure includes meeting allowances, monthly remuneration, and directors’ bonuses. A comparison with 2024 and the key changes are summarized as follows:

  • In 2025, a monthly remuneration was introduced for:
    • Chairman of the Board: Baht 30,000 per month
    • Independent Directors: Baht 25,000 per month

  • Meeting allowances remain unchanged from 2024

  • Directors’ bonus revised to be paid only to independent directors, at THB 200,000 per person per year

  • Other remuneration structures remain unchanged

Remuneration or Benefits Payable to the Board

MetricAmount (Baht)
Remunerations or benefits pending payment to the board of directors over the past year (baht)0

Supervision of Subsidiaries & Associated Companies

Supervision of Subsidiaries — Introduction

The company has an investment policy. This includes supervision of subsidiaries and associates. It will invest in businesses that are closely related or that bring benefits and support the company's business operations and take into account the returns of all stakeholders in order to strengthen stability and operating results.

Oversight Mechanism — Introduction

In supervising the operations of subsidiaries and associated companies, the Board of Directors will consider sending representatives of the Company who have qualifications and experience appropriate to the business in which the Company invests to be directors in subsidiaries and associated companies. of the said company This is so that the company can supervise the business and operations of its subsidiaries and associated companies as if they were a unit of the company. The company places great importance on having a good and transparent management system. Can be verified and will help maintain the benefits of the company's investments. The Company therefore requires the Company's representatives to manage the business of the subsidiaries and associated companies in the best interests of the Company and to ensure compliance with the laws related to the business operations of the subsidiaries and associated companies. In addition, sending representatives to act as directors in such subsidiaries and associated companies shall be in accordance with the Company's shareholding percentage in such subsidiaries and associated companies.

Does the Company Have Subsidiaries or Associated Companies?

No

Is There a Mechanism for Overseeing Subsidiaries and Associated Companies?

Yes

Mechanism for Overseeing Management of Subsidiaries

As of December 31, 2025, the company has not yet established any subsidiaries or joint ventures. According to the company's policy, if investments are made in subsidiaries or joint ventures, company representatives must be appointed as directors in proportion to the investment share. Additionally, the company must oversee internal control systems, financial accounting systems, and ensure the closure of accounts on a quarterly basis to facilitate the preparation of consolidated financial statements.

Oversight Mechanisms

Mechanism
Sending representatives to act as directors, executives or controlling persons in proportion to shareholdings
Defining the scope of powers, duties and responsibilities of directors and executives who represent the company in setting important policies
Disclosure of financial information and operating results
Transactions between the Company and related persons
Other important transactions
Internal control system of the subsidiary operating the core business is appropriate and sufficient in the subsidiary operating the core business

Agreements Between the Company and Shareholders in Managing Subsidiaries

none

Board Duty Performance — Overview

Board Duty Performance — Overall Description

The Board of Directors, as representatives of the shareholders, is responsible for overseeing the company's business operations in compliance with the law, objectives, articles of association, and resolutions of the shareholders' meetings. This includes adhering to the principles of good corporate governance as prescribed by the Stock Exchange of Thailand ("SET") and the 2017 Corporate Governance Code for Listed Companies issued by the Securities and Exchange Commission ("SEC") to ensure sustainable value creation for the company. Additionally, the Board of Directors oversees the establishment of the company's vision, mission, goals, operational direction, strategic plans, budget, and policies. It also monitors the company’s performance and financial status on a quarterly basis to ensure the company's adaptability to various changing factors that may impact the business. This enables the company to operate smoothly and enhance its competitive advantage in the future.

Furthermore, the Board ensures the adequacy of the company’s internal control system and risk management while ensuring the accurate and complete disclosure of financial reports in accordance with relevant financial reporting standards. This serves to build confidence among investors and shareholders.

Audit Committee Duty Performance

Results of the Audit Committee's Duty Performance in the Past Year

Summary of the Key Responsibilities of the Audit Committee and Their Opinions and Reports to the Board of Directors during the Year

1. Review of Financial Reports: The Audit Committee reviewed the quarterly and annual financial reports, which were audited and confirmed by the external auditor to comply with generally accepted accounting standards. The financial reports were presented with accurate and complete disclosures. The Committee invited the external auditor and management responsible for preparing the financial reports to attend each meeting where financial statements were reviewed before being presented to the Board of Directors for approval. The Audit Committee believes that the financial reports were prepared in accordance with generally accepted accounting standards and adequately disclosed in the financial statement notes. Furthermore, the Committee held a meeting with the external auditor without management present to allow independent discussions.

2. Assessment and Review of Internal Control Systems: The Audit Committee considered and approved the internal audit plan for the year 2025 and reviewed the internal control system through various sources, including audit reports from the external auditor, reports on the evaluation of the internal control system conducted by the outsourced internal auditor, Proud Advisory Co., Ltd., and reports from the Risk Management Working Team.The Audit Committee also reviewed the adequacy of the internal control system in accordance with the guidelines prescribed by the Office of the Securities and Exchange Commission of Thailand. The results of such reviews, together with the Committee’s opinions, were regularly reported to the Board of Directors and the management. This process ensures that the Company’s operations are supported by an appropriate and sufficient internal control system, enhancing operational effectiveness and efficiency, preventing or mitigating risks and potential losses, and ensuring that financial reports are accurate and reliable. The Company also continues to develop and improve the quality of its internal control system on an ongoing basis.

3. Oversight of Internal Audit Activities: The Audit Committee approved the appointment of Proud Advisory Co., Ltd., led by Mr. Parit Buapuen, as the external internal auditor based on their qualifications, including the sufficient number of staff, experience, knowledge, ability, and independence to perform the audit. The internal audit team evaluated the sufficiency of the internal control system based on established guidelines.

4. Compliance with Ethics, Laws, and Policies: The Audit Committee reviewed the corporate governance process, including the handling of complaints related to service quality, ethics, and fraud prevention. The Committee also monitored changes in securities and stock market laws and relevant regulations to ensure that the company operates in compliance with ethics, laws, and regulations. It is ensured that the company is continuously prepared for changes.

5. Review of Risk Management: The Audit Committee reviewed and provided opinions on the company’s organizational risks, risk management plans, and regular risk analysis reports from the risk management team. The Committee also supported the analysis of sustainability-related risks in ESG (Environmental, Social, and Governance) areas and reported the findings to the Board of Directors.

6. Review of Related Party Transactions and Potential Conflicts of Interest: The Audit Committee reviewed and provided opinions on the necessity and reasonableness of related party transactions and potential conflicts of interest, including contracts, agreements, and key terms, ensuring full and sufficient disclosure as required by the Stock Exchange of Thailand.

7. Selection and Appointment of Auditors: The Audit Committee evaluated the performance, knowledge, and understanding of the business by the auditors, the quality of their work, and the appropriateness of their fees. The Committee recommended the appointment of Office of Pitisevi Co., Ltd. as the external auditor for the year and proposed the annual audit fee to the Board of Directors for shareholder approval.

8. Evaluation of Performance and Review of the Charter: The Audit Committee conducted self-assessments both at the committee and individual levels and reviewed the Audit Committee Charter. This included evaluating the scope of duties and responsibilities in alignment with the Securities and Exchange Commission's guidelines. The results were submitted to the Board of Directors for approval.

9. Schedule of the Audit Committee Meetings for the Year 2026

Meeting No. 1/2026: Thursday, 26 February 2026, 4:00 – 5:30 PM

Meeting No. 2/2026: Wednesday, 13 May 2026, 4:00 – 5:30 PM

Meeting No. 3/2026: Tuesday, 11 August 2026, 4:00 – 5:30 PM

Meeting No. 4/2026: Wednesday, 11 November 2026, 4:00 – 5:30 PM

The Audit Committee has performed its duties and responsibilities in accordance with the Audit Committee Charter and as delegated by the Board of Directors with care and to the best of its ability. The Audit Committee is of the opinion that the company’s financial reports and disclosures are sufficient, appropriate, reliable, and in compliance with generally accepted accounting standards. The company has an effective and adequate internal control system and risk management practices that are suitable for the business operations. Additionally, related party transactions and information are disclosed adequately, and the company complies with good corporate governance principles. There has also been continuous development and improvement in the quality of the internal control system.

Executive Committee Duty Performance

Results of the Executive Committee's Duty Performance in the Past Year

In 2025, the Executive Committee performed its duties with key responsibilities summarized as follows:

  1. To consider and formulate business strategies, policies, and annual budgets for submission to the Board of Directors for approval, as well as to regularly monitor operating results on a monthly basis, and provide direction and recommendations to enhance the Company’s long-term competitiveness

  2. To review, monitor, and evaluate the Company’s business performance to ensure alignment with established targets, and to report such performance to the Board of Directors

  3. To consider the allocation of annual budgets and assess the feasibility of new projects, including undertaking projects deemed appropriate, through careful and prudent analysis of opportunities, risks, strengths, and weaknesses, in order to enhance business opportunities and generate sustainable returns

  4. To approve financial expenditures related to the Company’s normal business operations within the limits of the budget approved by the Board of Directors

  5. To oversee the Company’s management and operations to ensure compliance with applicable laws, ethical standards, and principles of good corporate governance, as well as to prevent and mitigate potential conflicts of interest within the organization

  6. To consider and monitor the Company’s operating results, and propose interim and annual dividend payments to the Board of Directors for approval

  7. To determine the organizational structure and management authority, including the appointment, hiring, transfer, termination, compensation, remuneration, and bonuses for executives at the Chief Officer level and above (or equivalent), except for the Chief Executive Officer

  8. To review the Executive Committee Charter to ensure that its roles and responsibilities remain appropriate and aligned with current circumstances and changes

  9. To conduct performance evaluations of the Executive Committee, both as a whole and on an individual basis, for the year 2025. The overall evaluation result was rated “Excellent,” and the results were reported to the Board of Directors for further improvement and disclosed in the Form 56-1 One Report / Annual Report

The Executive Committee has performed its duties within the scope of authority and responsibilities as defined in its Charter with due care, prudence, transparency, integrity, and reasonableness, taking into account the best interests of shareholders and all stakeholders. The Committee also ensures that the Company maintains efficient operations, complies with applicable laws, and adheres to good corporate governance principles, thereby supporting sustainable and stable business growth.

Contents